001     178456
005     20240229143547.0
024 7 _ |a 10.1186/s40478-021-01308-1
|2 doi
024 7 _ |a pmid:35012690
|2 pmid
024 7 _ |a altmetric:120640681
|2 altmetric
037 _ _ |a DKFZ-2022-00082
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ebrahimi, Azadeh
|0 P:(DE-He78)c1e6f8388afe92ba3e13be35e7bf54d8
|b 0
|e First author
|u dkfz
245 _ _ |a Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival.
260 _ _ |a London
|c 2022
|b Biomed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1646913253_14504
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B300#LA:B300#
520 _ _ |a Pleomorphic xanthoastrocytoma (PXA) in its classic manifestation exhibits distinct morphological features and is assigned to CNS WHO grade 2 or grade 3. Distinction from glioblastoma variants and lower grade glial and glioneuronal tumors is a common diagnostic challenge. We compared a morphologically defined set of PXA (histPXA) with an independent set, defined by DNA methylation analysis (mcPXA). HistPXA encompassed 144 tumors all subjected to DNA methylation array analysis. Sixty-two histPXA matched to the methylation class mcPXA. These were combined with the cases that showed the mcPXA signature but had received a histopathological diagnosis other than PXA. This cohort constituted a set of 220 mcPXA. Molecular and clinical parameters were analyzed in these groups. Morphological parameters were analyzed in a subset of tumors with FFPE tissue available. HistPXA revealed considerable heterogeneity in regard to methylation classes, with methylation classes glioblastoma and ganglioglioma being the most frequent mismatches. Similarly, the mcPXA cohort contained tumors of diverse histological diagnoses, with glioblastoma constituting the most frequent mismatch. Subsequent analyses demonstrated the presence of canonical pTERT mutations to be associated with unfavorable prognosis among mcPXA. Based on these data, we consider the tumor type PXA to be histologically more varied than previously assumed. Histological approach to diagnosis will predominantly identify cases with the established archetypical morphology. DNA methylation analysis includes additional tumors in the tumor class PXA that share similar DNA methylation profile but lack the typical morphology of a PXA. DNA methylation analysis also assist in separating other tumor types with morphologic overlap to PXA. Our data suggest the presence of canonical pTERT mutations as a robust indicator for poor prognosis in methylation class PXA.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a BRAF V600E
|2 Other
650 _ 7 |a DNA methylation array profiling
|2 Other
650 _ 7 |a Epithelioid glioblastoma
|2 Other
650 _ 7 |a Ganglioglioma
|2 Other
650 _ 7 |a Pleomorphic xanthoastrocytoma
|2 Other
650 _ 7 |a pTERT mutation
|2 Other
700 1 _ |a Korshunov, Andrey
|0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
|b 1
|u dkfz
700 1 _ |a Reifenberger, Guido
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Capper, David
|0 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
|b 3
|u dkfz
700 1 _ |a Felsberg, Joerg
|b 4
700 1 _ |a Trisolini, Elena
|b 5
700 1 _ |a Pollo, Bianca
|b 6
700 1 _ |a Calatozzolo, Chiara
|b 7
700 1 _ |a Prinz, Marco
|b 8
700 1 _ |a Staszewski, Ori
|b 9
700 1 _ |a Schweizer, Leonille
|b 10
700 1 _ |a Schittenhelm, Jens
|b 11
700 1 _ |a Harter, Patrick
|0 P:(DE-He78)b15b56a6ed37417d476470c60c0140ff
|b 12
700 1 _ |a Paulus, Werner
|b 13
700 1 _ |a Thomas, Christian
|b 14
700 1 _ |a Kohlhof-Meinecke, Patricia
|b 15
700 1 _ |a Seiz-Rosenhagen, Marcel
|b 16
700 1 _ |a Milde, Till
|0 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
|b 17
|u dkfz
700 1 _ |a Casalini, Maria Belen
|0 P:(DE-He78)1e5010244cbd57412baa2f0e2806a182
|b 18
700 1 _ |a Suwala, Abigail
|0 P:(DE-He78)c77fccff3e6c42b017b2e8a09813590c
|b 19
|u dkfz
700 1 _ |a Wefers, Annika K
|0 P:(DE-He78)32977c5abc127b0373ece54294a41f63
|b 20
|u dkfz
700 1 _ |a Reinhardt, Annekathrin
|0 P:(DE-He78)856d5c1d0205a79190ed88218ffaf9b2
|b 21
|u dkfz
700 1 _ |a Sievers, Philipp
|0 P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6
|b 22
|u dkfz
700 1 _ |a Kramm, Christof M
|b 23
700 1 _ |a Etminam, Nima
|b 24
700 1 _ |a Unterberg, Andreas
|b 25
700 1 _ |a Wick, Wolfgang
|0 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
|b 26
|u dkfz
700 1 _ |a Herold-Mende, Christel
|b 27
700 1 _ |a Sturm, Dominik
|0 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807
|b 28
|u dkfz
700 1 _ |a Pfister, Stefan M
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 29
|u dkfz
700 1 _ |a Sill, Martin
|0 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
|b 30
|u dkfz
700 1 _ |a Jones, David T W
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 31
|u dkfz
700 1 _ |a Schrimpf, Daniel
|0 P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc
|b 32
|u dkfz
700 1 _ |a Reuss, David E
|0 P:(DE-He78)d5149ffd74f42a2fa87a086d66645aaa
|b 33
|u dkfz
700 1 _ |a Aldape, Ken
|b 34
700 1 _ |a Abdullaev, Zied
|b 35
700 1 _ |a Sahm, Felix
|0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
|b 36
|u dkfz
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 37
|u dkfz
700 1 _ |a Stichel, Damian
|0 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17
|b 38
|e Last author
|u dkfz
773 _ _ |a 10.1186/s40478-021-01308-1
|g Vol. 10, no. 1, p. 5
|0 PERI:(DE-600)2715589-4
|n 1
|p 5
|t Acta Neuropathologica Communications
|v 10
|y 2022
|x 2051-5960
909 C O |p VDB
|o oai:inrepo02.dkfz.de:178456
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)c1e6f8388afe92ba3e13be35e7bf54d8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)b15b56a6ed37417d476470c60c0140ff
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)1e5010244cbd57412baa2f0e2806a182
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)c77fccff3e6c42b017b2e8a09813590c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)32977c5abc127b0373ece54294a41f63
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-He78)856d5c1d0205a79190ed88218ffaf9b2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 26
|6 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 28
|6 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 29
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 30
|6 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 31
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 32
|6 P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 33
|6 P:(DE-He78)d5149ffd74f42a2fa87a086d66645aaa
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 36
|6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 37
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 38
|6 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-01-28
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-01-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL COM : 2021
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-14T16:20:11Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-14T16:20:11Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-02-14T16:20:11Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-09
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-09
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ACTA NEUROPATHOL COM : 2021
|d 2022-11-09
920 2 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 0
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK ED ES zentral
|x 2
920 1 _ |0 I:(DE-He78)BE01-20160331
|k BE01
|l DKTK BE zentral
|x 3
920 1 _ |0 I:(DE-He78)FM01-20160331
|k FM01
|l DKTK FM zentral
|x 4
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 5
920 1 _ |0 I:(DE-He78)B310-20160331
|k B310
|l KKE Pädiatrische Onkologie
|x 6
920 1 _ |0 I:(DE-He78)B320-20160331
|k B320
|l KKE Neuroonkologie
|x 7
920 1 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pediatric Glioma
|x 8
920 0 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a I:(DE-He78)BE01-20160331
980 _ _ |a I:(DE-He78)FM01-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)B310-20160331
980 _ _ |a I:(DE-He78)B320-20160331
980 _ _ |a I:(DE-He78)B360-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21